Search Results - "Barclay, Murray"

Helicobacter pylori in New Zealand : current diagnostic trends and related costs by Kubovy, Jan, Barclay, Murray L

“…Ascertains Helicobacter pylori (Hp) diagnosis trends and cost within the Canterbury District Health Board (CDHB) catchment area over six consecutive years…”
Get full text

Cost-effectiveness of therapeutic drug monitoring in inflammatory bowel disease by McNeill, Richard P, Barclay, Murray L

“…[Display omitted] •Biologics are effective, but expensive, therapies for inflammatory bowel disease.•Therapeutic drug monitoring reduces biologic costs through…”
Get full text

Editorial: Monitoring methotrexate polyglutamates in Crohn's disease by Barclay, Murray L., Stamp, Lisa K.

“…LINKED CONTENT This article is linked to van de Meeberg et al papers. To view these articles, visit https://doi.org/10.1111/apt.17719 and…”
Get full text

Systematic review with meta‐analysis: SARS‐CoV‐2 stool testing and the potential for faecal‐oral transmission by Doorn, Amarylle S., Meijer, Berrie, Frampton, Chris M. A., Barclay, Murray L., Boer, Nanne K. H.

“…Summary Background Since the start of the COVID‐19 pandemic, there have been many scientific reports regarding gastrointestinal manifestations. Several reports…”
Get full text

The Spectrum of Perianal Crohn’s Disease in a Population-Based Cohort by Eglinton, Tim W, Barclay, Murray L, Gearry, Richard B, Frizelle, Frank A

“…BACKGROUND:Perianal Crohn’s disease represents a phenotype distinct from luminal Crohn’s disease and may follow a different course. To date, the only detailed…”
Get full text

How to prevent allopurinol hypersensitivity reactions? by Stamp, Lisa K., Barclay, Murray L.

“…Abstract Allopurinol hypersensitivity syndrome (AHS) is a severe and sometimes life-threatening adverse drug reaction. Although AHS is rare, the number of…”
Get full text

A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout by Stamp, Lisa K, Chapman, Peter T, Barclay, Murray L, Horne, Anne, Frampton, Christopher, Tan, Paul, Drake, Jill, Dalbeth, Nicola

“…To determine the efficacy and safety of allopurinol dose escalation using a treat-to-target serum urate (SU) approach. A randomised, controlled,…”
Get more information

Update on thiopurine pharmacogenetics in inflammatory bowel disease by Roberts, Rebecca L, Barclay, Murray L

“…Azathioprine and 6-mercaptopurine remain pivotal therapies for the maintenance of disease remission in patients with Crohn's disease and ulcerative colitis…”
Get full text

Relationship Between Adalimumab Concentrations, Antidrug Antibodies, and Disease Activity in Rheumatoid Arthritis: A Cross-Sectional Observational Study by Stamp, Lisa K, Keating, Paula, Frampton, Christopher, Barclay, Murray L, Fanning, Niamh, Millier, Melanie, Hessian, Paul A, O'Donnell, John L

“…To determine the influence of patient characteristics and disease activity on adalimumab (ADA) concentrations; to assess the relationships between ADA…”
Get full text

Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study by Stamp, Lisa K, Chapman, Peter T, Barclay, Murray, Horne, Anne, Frampton, Christopher, Tan, Paul, Drake, Jill, Dalbeth, Nicola

“…To determine the long-term safety and efficacy of allopurinol dose escalation (DE) to achieve target serum urate (SU) in gout. People, including those with…”
Get more information

Population-based cases control study of inflammatory bowel disease risk factors by Gearry, Richard B, Richardson, Ann K, Frampton, Christopher M, Dodgshun, Andrew J, Barclay, Murray L

“…Background and Aim:  The rapid increase in inflammatory bowel disease (IBD) incidence confirms the importance of environment in its etiology. We aimed to…”
Get full text

Evaluation of the Homogenous Mobility Shift Assay for Infliximab and Adalimumab Anti-drug Antibody Detection in the Clinical Laboratory by Keating, Paula Elizabeth, Hock, Barry D, Chin, Paul K L, O'Donnell, John Liston, Barclay, Murray Lindsay

“…Detecting antidrug antibodies (ADAs) against infliximab or adalimumab is useful for therapeutic drug monitoring. Various ADA detection methods exist, and…”
Get full text

Immediate effect of caffeine on sympathetic nerve activity: why coffee is safe? A single-centre crossover study by Butler, Jennifer M., Frampton, Christopher M., Moore, Grant, Barclay, Murray L., Jardine, David L.

“…Purposes Habitual coffee drinking is ubiquitous and generally considered to be safe despite its transient hypertensive effect. Our purpose was to determine the…”
Get full text

Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment by Stamp, Lisa K., O'Donnell, John L., Zhang, Mei, James, Jill, Frampton, Christopher, Barclay, Murray L., Chapman, Peter T.

“…Objective To determine the efficacy and safety of increasing the allopurinol dose above the proposed creatinine clearance–based dose in patients with gout…”
Get full text

A 1 g dose of intravenous iron is sufficient to treat iron deficiency anaemia by Karim, Syarihan, Butler, Jennifer M., Barclay, Murray L.

“…One hundred and ninety‐four patient episodes were audited for response to a standardised 1 g intravenous iron infusion for medical outpatients with iron…”
Get full text

Population-based epidemiology study of autoimmune hepatitis: A disease of older women? by Ngu, Jing H, Bechly, Kristen, Chapman, Bruce A, Burt, Michael J, Barclay, Murray L, Gearry, Richard B, Stedman, Catherine A M

“…Background and Aim:  The etiology of autoimmune hepatitis (AIH) is unknown, and limited epidemiological data are available. Our aim was to perform a population…”
Get full text

Perianal Disease Predicts Changes in Crohn's Disease Phenotype-Results of a Population-Based Study of Inflammatory Bowel Disease Phenotype by TARRANT, Kelly M, BARCLAY, Murray L, FRAMPTON, Christopher M. A, GEARRY, Richard B

“…The Montreal classification system of inflammatory bowel disease (IBD) provides a framework for describing disease phenotype. We aimed to describe changes in…”
Get full text

Late-onset Rise of 6-MMP Metabolites in IBD Patients on Azathioprine or Mercaptopurine by Munnig-Schmidt, Erik, Zhang, Mei, Mulder, Chris J, Barclay, Murray L

“…Abstract Background The thiopurines azathioprine and mercaptopurine remain pivotal maintenance treatments in inflammatory bowel disease (IBD); however, up to…”
Get full text

Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives by de Boer, Nanne K H, Peyrin-Biroulet, Laurent, Jharap, Bindia, Sanderson, Jeremy D, Meijer, Berrie, Atreya, Imke, Barclay, Murray L, Colombel, Jean-Frederic, Lopez, Anthony, Beaugerie, Laurent, Marinaki, Anthony M, van Bodegraven, Adriaan A, Neurath, Markus F

“…Abstract Thiopurines, available as azathioprine, mercaptopurine, and thioguanine, are immunomodulating agents primarily used to maintain corticosteroid-free…”
Get full text

Maternal thiopurine metabolism during pregnancy in inflammatory bowel disease and clearance of thiopurine metabolites and outcomes in exposed neonates by Flanagan, Emma, Wright, Emily K., Hardikar, Winita, Sparrow, Miles P., Connell, William R., Kamm, Michael A., De Cruz, Peter, Brown, Steven J., Thompson, Alexander, Greenway, Anthea, Westley, Ian, Barclay, Murray, Ross, Alyson L., Kiburg, Katerina V., Bell, Sally J.

“…Summary Background Azathioprine and mercaptopurine are considered safe during pregnancy. However, the pharmacokinetic effects of pregnancy on thiopurine…”
Get full text